CERE - Cerevel Corp Market Capitalization-to-Revenue Ratio
Cerevel Therapeutics (CERE) is implementing automated screening platforms to accelerate the discovery of active compounds, leveraging an optimized network of raw material suppliers for research. The revenue valuation metric reflects the price action, while the value confirms the current market valuation. The company focuses on developing therapies for Parkinson's disease and schizophrenia, targeting the massive CNS drug market.
Metric breakdowns and analytics for Cerevel Therapeutics (CERE)
- current price and projected stock value:
- market capitalization statistics:
- book capitalization indicators:
- business debt structure and liquidity details:
Debt to Capital Cerevel Therapeutics|CERE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Cerevel Therapeutics|CERE - Company Aggregate Debts|Debts to Book Capitalization Cerevel Therapeutics|CERE - Company Long-Term Debt|Current Liabilities Cerevel Therapeutics|Immediate Liquidity cerevel.com
- earnings and market ratios statistics:
CERE - Net Income|Projected Future Earnings Cerevel Therapeutics|CERE - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Cerevel|CERE - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Cerevel Corp|CERE - Operating profit EBITDA|Net earnings per share for the last 12 months Cerevel Therapeutics|CERE - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months cerevel.com|CERE - Earnings growth in current year|Expected earnings per share growth for next year Cerevel Therapeutics
- issuer revenue and sales details:
General company analysis:CERE Cerevel Therapeutics Inc
Cerevel Therapeutics (CERE) is optimizing its neuro-drug discovery process through laboratory robotics, which reduces costs and impacts the market value of its assets. This price-to-sales ratio correlates current market capitalization with actual sales volume, allowing investors to promptly assess the efficiency of the business model between reports and determine the extent to which market expectations for the company's future profitability are overextended.
Competitors of Cerevel Therapeutics
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX (Protagenic Therapeutics) - Market Cap to Sales Volume|P/S Multiple KTTA|Price-to-Revenue Coefficient Cortigent|P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|Cara Therapeutics Inc. - P/S Multiple|Chromocell Therapeutics (CHRO) - Market Cap to Revenue|ELYM: P/S Multiple|Market Cap to Revenue Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - P/S Multiple|Marinus - Price-to-Sales Ratio|P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple SAGE (Sage Therapeutics Inc)|Price-to-Revenue Coefficient Synaptogenix Inc. (SNPX)|TRVN - Price-to-Revenue Ratio|vigilneuro.com (VIGL) - Market Cap to Revenue|WENA: P/S Multiple
